Stryker Stock

$390.59

0.22% today

NYSE, Jul 15, 10:00 pm CET

ISIN

US8636671013

Symbol

SYK

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Stryker Stock price

$391.46

+208.75 114.25% 5Y

NYSE, Closing price Mon, Jul 14 2025

+2.00 0.51%

ISIN

US8636671013

Symbol

SYK

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$149.6b

Enterprise Value

$164.0b

Net debt

$14.4b

Cash

$2.4b

Shares outstanding

382.1m

Valuation (TTM | estimate)

P/E

52.9 | 29.0

P/S

6.4 | 6.0

EV/Sales

7.1 | 6.6

EV/FCF

45.8

P/B

7.2

Dividends

DPS

$3.24

Yield 1Y | 5Y

0.8% | 1.1%

Growth 1Y | 5Y

6.2% | 8.7%

Payout 1Y | 3Y

41.8% | 41.1%

Increased

15 Years

Financials (TTM | estimate)

Revenue

$23.2b | $25.0b

EBITDA

$5.8b | $7.1b

EBIT

$5.2b | $6.5b

Net Income

$2.9b | $5.2b

Free Cash Flow

$3.6b

Growth (TTM | estimate)

Revenue

10.8% | 10.7%

EBITDA

13.1% | 25.3%

EBIT

14.6% | 29.2%

Net Income

-14.9% | 72.1%

Free Cash Flow

25.2%

Financial Health

Equity Ratio

48.0%

Return on Equity

14.5%

ROCE

13.6%

ROIC

10.8%

Debt/Equity

0.8

EPS

$7.4

FCF per Share

$9.4

Short interest

1.4%

Employees

53k

Rev per Employee

$430.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Stryker Stock Analysis

Unlock Scores for Free

??

37 Analysts have issued a Stryker forecast:

27x Buy

73%

10x Hold

27%

More details on Analyst Estimates Including Price Targets

37 Analysts have issued a Stryker forecast:

Buy

73%

Hold

27%

Analyst Estimates with Stock Price Targets

Financial data from Stryker

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	23,218 23,218	11% 11% 100%
- Direct Costs	8,225 8,225	9% 9% 35%
Gross Profit	14,993 14,993	12% 12% 65%
- Selling and Administrative Expenses	7,715 7,715	11% 11% 33%
- Research and Development Expense	1,451 1,451	8% 8% 6%
EBITDA	5,827 5,827	13% 13% 25%
- Depreciation and Amortization	637 637	2% 2% 3%
EBIT (Operating Income) EBIT	5,190 5,190	15% 15% 22%
Net Profit	2,859 2,859	15% 15% 12%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Stryker Stock News

Neutral

GlobeNewsWire

●

4 days ago

North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

Discover comprehensive insights with the "North America Cystoscopes Market Outlook to 2033" report. Analyze market data, company shares, and segment details for Flexible and Rigid Cystoscopes. Develop strategic plans and investment strategies by identifying growth opportunities in the North America Cystoscopes market. Discover comprehensive insights with the "North America Cystoscopes Market Ou...

Neutral

GlobeNewsWire

●

14 days ago

Stryker to announce financial results for its second quarter of fiscal year 2025

Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarte...

Neutral

Business Wire

●

20 days ago

Stryker receives FDA clearance for Incompass Total Ankle System

PORTAGE, Mich.--(BUSINESS WIRE)--Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe arthritis-related ankle joint damage.

More Stryker News

Company Profile

Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.

Head office	United States
CEO	Kevin Lobo
Employees	53,000
Founded	1941
Website	www.stryker.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now